Intravesical valrubicin in the treatment of carcinoma in situ of the bladder

Bibliography

• Cancer Statistics 2003. CA Cancer. j. (2030) 50:12–13.
   Google Scholar
• WINGO PA RIES LA, GIOVINO GA etal.:Annual report to the nation on the status of cancer, 1973–1996, with a special section on lung cancer and tobacco smoking. j. Nati Cancer List (1999) 91(8):675–690.
   Google Scholar
• SAXMAN SB, PROPERT KJ, EINHORN LH et al.: Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. j. Gun. Oncol (1997) 15(7):2564–2569.
   Google Scholar
• LOEHRER PJ, EINHORN LH, ELSON PJ et al.: A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. j. Oncol. (1992) 10(7):1066–1073.
   Google Scholar
• JONES HC, SWINNEY J: Thiotepa in the treatment of tumors of the bladder. Lancet (1961) 2:615.
   PubMed Web of Science ®Google Scholar
• SMITH JA JR, LABASKY RF, COCKETT AT etal.: Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, Ti and TIS). The American Urological Association. J. Ural. (1999) 162(5):1697–1701.
   Google Scholar
• ALTHAUSEN AF, PROUT GR Jr., DALY JJ: Noninvasive papillary carcinoma of the bladder associated with carcinoma in situ j. UroL (1976) 116:575.
   Google Scholar
• NADLER RB, CATALONA WJ, HUDSON MA etal.: Durability of the tumor-free response for intravesical bacillus Calmette-Guerin therapy. J. UroL (1994) 157:367.
   Google Scholar
• NSEYO UO, LAMM DL: Immunotherapy of bladder cancer. Seminars in Surgical Oncology (1997) 13(5):342–349.
   PubMedGoogle Scholar
• PATARD JJ, SAINT E VELOTTI F etal.: Immune response following intravesical bacillus Calmette-Guerin instillations in superficial bladder cancer: a review. UroL Res. (1998) 26(3):155–159.
   Google Scholar
• KURTH KH, BOUFFIOUX C, SYLVESTER R etal.: Treatment of superficial bladder tumors: achievements and needs. The EORTC Genitourinary Group. Eur Ural. (2000) 37\(Suppl. 3):1–9.
   Google Scholar
• BLUM RH, GARNICK MB, ISRAEL Met al.: Preclinical rationale and phase I clinical trial of the adriamycin analog, AD 32. Recent Results Cancer Res (1981) 76:7–15.
   Google Scholar
• SILBER R, LIU LF, ISRAEL M etal.: Metabolic activation of N-acylanthracyclines recedes the interaction with DNA topoisomerase II. NCI Monogr. (1987) 4:111–115.
   Google Scholar
• WANI MK, KOSEKI Y, YARBER RH etal.: Rationale for intralesional valrubicin in chemoradiation of squamous cell carcinoma of the head and neck. Laryngoscope (2000) 110(12):2026–2032.
   Google Scholar
• MARZIN D, JASMIN C, MARAL R etal.: Mutagenicity of eight anthracycline derivatives in five strains of Salmonella typhimuriun. Eur j. Cancer Chu arra (1983) 19:641–647.
   Google Scholar
• Medeva Pharmaceuticals, Inc. Valstar® (valrubicin) sterile solution for intravesical instillation prescribing information. Rochester, NY (1999).
   Google Scholar
• NIELL HB, HUNTER RF, HERROD HG et al.: Effect of N-trifluoroacetyladriamycin-14-valerate (AD-32) on human bladder tumor cell lines. Cancer Chemother Marmara (1987) 19:47–52.
   PubMedGoogle Scholar
• ISRAEL M, IDRISS PVT, KOSEKI Y etal.: Comparative effects of adriamycin and DNA-non-binding analogues on DNA, RNA, and protein synthesis in vi/m. Cancer Chernother PharmacoL (1987) 20:277–284.
   Google Scholar
• KRISHAN A DUFF K, ISRAEL M, GANAPATHI R: Comparative effects of adriamycin and N-trifluoracetyladriamycin-14-valerate on cell kinetics, chromosomal damage, and macromolecular synthesis in vitm. Cancer Res. (1981) 41:2745–2750.
   PubMedGoogle Scholar
• CHOW K-C, MACDONALD rn, ROSS WE: DNA binding by epipodophyllotoxins and N-acyl anthracyclines: implications for mechanism of topoisomerase II inhibition. Mal Marmara (1988) 34(4):467–473.
   Google Scholar
• LOTHSTEIN L, SUTTLE DP ROATEN JF, KOSEKI Y, ISRAEL M, SWEATMAN TW: Catalytic inhibition of DNA topoisomerase II by N-benzyladriamycin (AD 288). Biochem. PharmacoL (2003) 160(11):1621–1628.
   Google Scholar
• ISRAEL M, MODEST EJ, FREI E III: N-trifluoracetyladriamycin-14-valerate, an analog with greater experimental antitumor activity and less toxicity than adriamycin. Cancer: Res (1975) 35:1365–1368.
   PubMed Web of Science ®Google Scholar
• VECCHI A, CAIRO M, MANTOVANI A et al.: Comparative antineoplastic activity of adriamycin and N-trifuoroacetyladriamycin-14-valerate. Cancer Treat. Rep. (1978) 62:111–117.
   PubMedGoogle Scholar
• HENDERSON IC, BILLINGHAM M, ISRAEL M etal.: Comparative cardiotoxicity studies with adriamycin (ADR) and AD 32 in rabbits (abstract no. 632). Proceedings of the Amedcan Association of Cancer Research (1978) 19:158.
   Google Scholar
• ZIRVI KA, GILANI SH, HILL GJ: Embryotoxic effects of doxorubicin and N-trifluoroacetyladriamycin-14-valerate (AD-32). Teratology(1985) 31:247–252.
   PubMedGoogle Scholar
• PATTERSON AL, GREENBERG RE, WEEMS L etal.: Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer. Urology (2000) 56(2):232–235.
   Google Scholar
• ISRAEL M, KARKOWSKY AM, KHETARPAL VK Distribution of radioactivity and anthracycline-fluorescence in tissues of mice one hour after [14C1-labeled AD 32 administration: evidence for tissue aglycone formation. Cancer Chemother. PharmacoL (1981) 6:25–30.
   PubMedGoogle Scholar
• ABBRUSSI R, RIZZARDINI M, BENIGNI A etal.: Possible relevance of N-trifluoroacetyladriamycin-14-valerate (AD 41) in the antitumoral activity of N-trifluoroacetyladriamycin-14-valerate (AD 32) in tumor-bearing mice. I. Pharmacokinetic evidence. Cancer Treat RT. (1980) 64:873–878.
   Google Scholar
• SWEATMAN TW, PAYNE C, PATTERSON L etal.: Penetration of intravesical N- trifluoroacetyladriamycin-14-valerate into human urinary bladder tissue; a clinical pharmacology study. h Annual Meeting of the American Association for Cancer Research (AACR). Washington, DC, USA (1996).
   Google Scholar
• BURKE TG, ISRAEL M, SESHADRI R etal.: A fluorescence study examining how 14-valerate side chain substituition modulates anthracycline binding to small unilamellar phospholipid vesicle& Biochern. Biophys. Acta. (1989) 982(1):123–130.
   Google Scholar
• STEINBERG G, BAHNSON R, BROSMAN S etal.: Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. j. Ural. (2003) 163(3):761–767.
   Google Scholar
• GREENBERG RE, BAHNSON RR, WOOD D etal.: Initial report on intravesical administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder. Urology (1997) 49(3):471–475.
   Google Scholar
• PAGANO E BASSI P GALETTI TP etal.: Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification. UroL (1991) 145(1):45–50.
   Google Scholar